DEMANT: Rising Share Buybacks Will Drive Medium-Term Upside Momentum

Key Takeaways

• Rising hearing health awareness and reduced stigma, combined with demographic trends, are expected to boost long-term demand and support recovery in revenues.
  
• Investment in advanced products and retail expansion positions Demant for premium market share, scalable service revenues, and enhanced profitability as conditions improve.
  
• Macroeconomic uncertainty, shifting geographic mix, and increased competition are reducing margins and profitability, while persistent volatility challenges long-term growth and earnings stability.

Catalysts

Operates as a hearing healthcare company in Europe, North America, Asia, Pacific region, and internationally.

• Current market uncertainty and consumer hesitancy, especially among first-time users, are leading to postponed purchases and upgrades, suppressing near-term revenue growth; as global economic conditions and consumer confidence normalize, underlying demographic demand from an aging population is expected to return, providing a tailwind for top-line growth and recurring revenue recovery.
  
• Increased public focus on hearing health, combined with initiatives to reduce stigma around hearing aids and greater awareness of long-term negative consequences of untreated hearing loss, suggest that penetration rates could rise, supporting volume growth and eventually higher revenues as macro headwinds diminish.
  
• Continued heavy investment in R&D and ongoing commitment to launching two major product updates annually (with a robust pipeline), including advancements in AI-enabled and connected hearing devices, position Demant to capture premium share with differentiated features, positively impacting future net margins and maintaining pricing power as digital adoption accelerates.
  
• Expansion of the hearing care retail and clinic network (including the KIND Group acquisition) increases access to care in strategically important geographies, paving the way for cross-selling of services and devices, growing high-margin recurring service revenues and improving long-term earnings stability and scalability.
  
• Operational discipline with tightened cost control during periods of weak market growth, alongside plans for efficiency gains and scale benefits from integration, positions Demant to expand margins as volumes recover-enabling a more leveraged return to profit growth once secular demand trends reassert themselves.

Demant Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Demant's revenue will grow by 8.4% annually over the next 3 years.
• Analysts assume that profit margins will increase from 10.3% today to 12.1% in 3 years time.
• Analysts expect earnings to reach DKK 3.5 billion (and earnings per share of DKK 17.22) by about June 2029, up from DKK 2.4 billion today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as DKK4.0 billion.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 17.9x on those 2029 earnings, down from 22.3x today. This future PE is lower than the current PE for the GB Medical Equipment industry at 28.7x.
• Analysts expect the number of shares outstanding to decline by 0.31% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 6.44%, as per the Simply Wall St company report.

Risks

• Persistent macroeconomic uncertainty and consumer cautiousness have led to lower-than-expected market growth, causing both delays in new purchases and upgrades of hearing aids-this reduces overall demand and impacts revenue and profitability.
  
• Shift in sales toward lower ASP (average selling price) geographies and product mixes (e.g., growth mainly outside the US and in free-to-client categories in key markets like France) has led to declining global ASP and unfavorable geographic mix; this erodes group gross margins and reduces EBIT.
  
• Intensifying competition-especially as more suppliers split large retailer contracts (e.g., cost channel dynamics with Sonova's return)-creates ongoing risk of lost market share and necessitates higher operational and promotional spending, further impacting net margins.
  
• Diagnostic business remains challenged by postponed investments, particularly in the US, due to ongoing economic uncertainty and tight government budgets, which could lead to prolonged revenue stagnation in this segment.
  
• Heightened market volatility and lack of consistent secular growth make long-term planning difficult and increase the risk that Demant's current margin pressures (from operational leverage, geographic mix, and market dynamics) could persist or worsen, constraining earnings growth over the long term.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of DKK251.11 for Demant based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of DKK280.0, and the most bearish reporting a price target of just DKK210.0.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be DKK29.2 billion, earnings will come to DKK3.5 billion, and it would be trading on a PE ratio of 17.9x, assuming you use a discount rate of 6.4%.
• Given the current share price of DKK250.6, the analyst price target of DKK251.11 is 0.2% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.